SimplyTest® has launched a groundbreaking saliva-based test to detect high-risk strains of oral human papillomavirus (HPV), a major cause of oropharyngeal cancers. Designed for use in dental and functional medicine practices, SimplyTest Oral HPV test provides a simple, accurate alternative to traditional screening methods.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251028293063/en/

SimplyTest has launched a groundbreaking saliva-based test to detect high-risk strains of oral human papillomavirus (HPV), a major cause of oropharyngeal cancers. Designed for use in dental and functional medicine practices, SimplyTest Oral HPV test provides a simple, accurate alternative to traditional screening methods.

“As we continue to expand the SimplyTest platform, our mission remains clear: to make advanced diagnostic insights available at the very first point of care,” Damon Silvestry, CEO of SimplyTest, said. “The Oral HPV test delivers on that vision by empowering dental and functional medicine providers to detect high-risk HPV earlier, when timely intervention can make the greatest difference in patient outcomes.”

Unlike conventional approaches that rely on visual exams or uncomfortable swab-based tests, SimplyTest uses painless sampling in conjunction with a high-complexity nucleic acid assay to identify clinically significant HPV serotypes associated with oral and pharyngeal cancers. It detects multiple high-risk HPV strains, including HPV-16, 18, 31, 33, 35, 39, 45 and others. Results are typically available within 24-48 hours of lab receipt.

“The Oral HPV test was designed to make detection of high-risk HPV strains more accessible, more accurate and far less invasive,” said Dr. Joel Peek, Chief Innovation Officer at SimplyTest. “By enabling dentists and other providers to screen for high-risk HPV with a simple saliva sample, we’re helping close a critical gap in cancer prevention.”

The SimplyTest Oral HPV test is currently offered as a laboratory-developed test (LDT) under CLIA and CAP-accredited guidelines. It meets the stringent validation standards required for high-complexity diagnostics and is intended for use within SimplyTest’s accredited laboratory.

Oropharyngeal cancers related to HPV have been on the rise, especially among younger, non-smoking adults. Despite this trend, regular screening remains uncommon due to the lack of accessible, reliable tools. Most dentists still rely on visual assessments, which may not detect infections in early stages.

SimplyTest bridges this gap by offering an objective, lab-based result that complements clinical exams and empowers providers to recommend timely follow-up care or additional testing.

For more information, visit https://www.simplytest.solutions/tests/oral-hpv.

About SimplyTest

SimplyTest® is redefining the starting point of care through next-generation salivary science. The SimplyTest platform delivers fast, non-invasive screenings that empower healthcare providers to detect microbial risks earlier, personalize treatment with precision and connect oral health to whole-body outcomes. SimplyTest goes beyond traditional testing and diagnostics. It is a provider-focused platform that transforms cutting-edge salivary science into earlier insights and more effective care pathways to unlock greater revenue potential for providers while lowering costs across the healthcare system. To learn more, visit https://www.simplytest.solutions.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251028293063/en/

Designed for use in dental and functional medicine practices, SimplyTest Oral HPV test provides a simple, accurate alternative to traditional screening methods for high-risk Oral HPV strains.